Main
node-negative stage IIB/C disease, resected stage IIB/C, melanoma
MELANOMA
The incidence of melanoma is rising worldwide, and patients with node-negative stage IIB/C disease comprise a large population at significant risk of recurrenceCheckpoint inhibitors have transformed the adjuvant treatment landscape of resectable stage III and stage IV melanomaHere we present a pre-specified interim analysis of the ongoing, randomized, double-blind, phase 3 CheckMate 76K trial evaluating nivolumab versus placebo as adjuvant treatment for patients with resected stage IIB/C melanoma, including the primary analysis of RFS.